Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma
Part of paid clinical trials in Encinitas, California.
- Sponsor
- San Diego Pacific Oncology & Hematology Associates
- Study ID
- NCT00538005
- Phase
- PHASE1/PHASE2
- Status
- Unknown
Conditions
- Melanoma (Skin)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- bevacizumab — BIOLOGICAL
- oxaliplatin — DRUG
- sorafenib tosylate — DRUG
Study Details
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of malignant melanoma by blocking blood flow to the tumor. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sorafenib together with bevacizumab and oxaliplatin may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side-effects and best dose of sorafenib when given together with bevacizumab and oxaliplatin and to see how well it works in treating patients with metastatic malignant melanoma.
Key Dates
- First listed
- Oct 2, 2007
- Start date
- May 31, 2007
- Status verified
- Jul 2009
- Primary completion
- Jul 31, 2009
Study Design
- Enrollment
- 54 participants (estimated)
- Primary purpose
- TREATMENT
Primary Outcome Measure
Maximum tolerated dose of sorafenib tosylate when administered with bevacizumab and oxaliplatin
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| San Diego Pacific Oncology and Hematology Associates, Incorporated - Encinitas | Encinitas | California | 92024 |
Find similar trials in Encinitas, CA
Related Studies
- Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory MelanomaPHASE2 · Recruiting · University of California, Irvine · Orange, California
- A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid TumorsPHASE1/PHASE2 · Recruiting · Hummingbird Bioscience · La Jolla, California
- Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanomaPHASE2 · Not Yet Recruiting · University of California, Irvine · Orange, California
- Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain MetastasesPHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas